Lisa A. Brenner, PhD
University of Colorado, Anschutz Medical Campus, Departments of Psychiatry, Physical Medicine and Rehabilitation, and Neurology
Dr. Brenner has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Despite the increased attention drawn to TBI, I often hear statements from mental health providers like, “I don’t see anybody in my clinic who has a history of TBI,” or, “People with more severe injuries don’t seek mental health services.”
Long-time editorial board member Ivan Goldberg passed away on November 26, 2013. Dr. Goldberg was a psychopharmacologist in New York and the founder of the Depression Central website and one of the largest psychopharmocology listservs in the world. Dr. Goldberg joined the TCPR editorial board in 2006. He will be missed.
Bret A. Moore, PsyD, ABPP
Board-Certified Clinical Psychologist, San Antonio, TX
Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Former active duty military and current civilian psychologist Dr Bret Moore provides tips and advice for compassionately and effectively treating returning veterans.
Varenicline (Chantix) is a nicotine partial agonist that is approved by the FDA for smoking cessation. Since July 1, 2009, the FDA has also required a “black box warning” based on postmarketing reports of adverse neuropsychiatric effects.
In November, drug giant Johnson & Johnson (J&J) and its subsidiaries agreed to pay $2.2 billion in fines and fees for wrongdoing related to kickbacks and misbranding of a number of their medications.
Kelly Brogan, MD
Clinical Instructor in Psychiatry, NYU School of Medicine
Dr. Brogan has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
We have all bumped up against the limits of the current model of antidepressant treatments for depression: the patient who comes in with a laundry list of failed medication trials, or a number of other complaints depicting a portrait of malaise—aches, pains, anhedonia, fatigue, brain fog, digestive woes—that don’t really respond to currently available agents. What if shifting our thinking about underlying causes might hold the answer to treatment of these individuals?